Citadel Advisors’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Citadel Advisors’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-18,173	Closed	-$736	–	15740
2023 Q1	$736	Buy	+18,173	New	+$1.25K	﹤0.01%	14425

Citadel Advisors's EUCRW Position: Q2 2023 in Review

Citadel Advisors sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 18,173 shares — an estimated $736 sold.

Citadel Advisors first reported a position in EUCRW in Q1 2023 and held it in 1 quarter. The position peaked at $736 in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Citadel Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 18,173 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $736.
Citadel Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2023 and held it in 1 quarter.
Citadel Advisors's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $736 in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.